AC Immune (ACIU) Non-Current Assets (2015 - 2026)
AC Immune (ACIU) posted quarterly Non-Current Assets of $73.3 billion for Q1 2026, up 111635.33% year-over-year from N/an in Q1 2025, and up 160.63% quarter-over-quarter from -$120.8 billion in Q4 2025.
AC Immune (ACIU) Non-Current Assets (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Non-Current Assets for 12 consecutive years, with $73.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 111635.33% year-over-year to $73.3 billion; the TTM figure through Mar 2026 stood at -$47.4 billion (down 18252.19% YoY), while the FY2025 annual figure was -$116.5 billion, down 173275.36% from the prior year.
- Non-Current Assets advanced to $73.3 billion in Q1 2026 per ACIU's latest filing, from -$120.8 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $73.3 billion in Q1 2026 and bottomed at -$191.7 billion in Q1 2022.
- Historically, Non-Current Assets has averaged -$32.0 billion across 5 years, with a median of $63.5 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 234740.01% — and 2026, when it jumped 111635.33%.
- AC Immune's Non-Current Assets stood at $60.0 million in 2022, then plunged by 234740.01% to -$140.9 billion in 2023, then soared by 100.05% to $67.3 million in 2024, then tumbled by 179742.36% to -$120.8 billion in 2025, then jumped by 160.63% to $73.3 billion in 2026.
- Business Quant data shows ACIU's Non-Current Assets at $73.3 billion in Q1 2026, -$120.8 billion in Q4 2025, and $72.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 72.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.12 Mn |
| Mar 31, 2026 | 73.26 Bn |
| Dec 31, 2025 | -120.82 Bn |
| Sep 30, 2025 | 72.33 Mn |
| Jun 30, 2025 | 70.56 Mn |
| Mar 31, 2025 | 65.56 Mn |
| Dec 31, 2024 | 67.26 Mn |
| Sep 30, 2024 | 65.40 Mn |
| Jun 30, 2024 | 63.02 Mn |
| Mar 31, 2024 | 65.77 Mn |
| Dec 31, 2023 | -140.89 Bn |
| Sep 30, 2023 | 64.31 Mn |
| Jun 30, 2023 | 63.48 Mn |
| Mar 31, 2023 | 62.13 Mn |
| Dec 31, 2022 | 60.04 Mn |
| Sep 30, 2022 | 60.01 Mn |
| Jun 30, 2022 | -164.44 Bn |
| Mar 31, 2022 | -191.72 Bn |
| Dec 31, 2021 | -219.47 Bn |
| Sep 30, 2021 | -212.79 Bn |